1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama 295:2164-2167(2006). https://doi.org/10.1001/jama.295.18.2164
2. Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Annals of surgery 254:653-660(2011). https://doi.org/10.1097/SLA.0b013e318230036d
3. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. Jama 317:1338-1348(2017). https://doi.org/10.1001/jama.2017.2719
4. Gao M, Ge M, Ji Q, et al. 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma. Cancer biology & medicine 14:203-211(2017). https://doi.org/10.20892/j.issn.2095-3941.2017.0051
5. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115:3801-3807(2009). https://doi.org/10.1002/cncr.24416
6. Giordano D, Gradoni P, Oretti G, Molina E, Ferri T. Treatment and prognostic factors of papillary thyroid microcarcinoma. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 35:118-124(2010). https://doi.org/10.1111/j.1749-4486.2010.02085.x
7. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association 26:1-133(2016). https://doi.org/10.1089/thy.2015.0020
8. Pedrazzini L, Baroli A, Marzoli L, Guglielmi R, Papini E. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva endocrinologica 38:269-279(2013). https://doi.org/10.1038/nutd.2013.31
9. Zheng X, Wei S, Han Y, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Annals of surgical oncology 20:2266-2273(2013). https://doi.org/10.1245/s10434-012-2851-z
10. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 98:31-40(2003). https://doi.org/10.1002/cncr.11442
11. Jeon MJ, Kim WG, Choi YM, et al. Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas. Thyroid : official journal of the American Thyroid Association 26:161-168(2016). https://doi.org/10.1089/thy.2015.0375
12. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 13:498-512(2007). https://doi.org/10.4158/ep.13.5.498
13. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid : official journal of the American Thyroid Association 24:27-34(2014). https://doi.org/10.1089/thy.2013.0367
14. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA: a cancer journal for clinicians 67:93-99(2017). https://doi.org/10.3322/caac.21388
15. Zhang XY, Song HJ, Qiu ZL, et al. Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with (131)I. Endocrine 62:149-158(2018). https://doi.org/10.1007/s12020-018-1678-1
16. Song HJ, Qiu ZL, Shen CT, Wei WJ, Luo QY. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. European journal of endocrinology 173:399-408(2015). https://doi.org/10.1530/eje-15-0296
17. Choi YM, Kim WG, Kwon H, et al. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma. European journal of endocrinology 175:165-172(2016). https://doi.org/10.1530/eje-16-0237
18. Sohn SY, Kim HI, Kim YN, Kim TH, Kim SW, Chung JH. Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up. Clin Endocrinol (Oxf) 88:318-326(2018). https://doi.org/10.1111/cen.13489
19. Qiu ZL, Shen CT, Sun ZK, et al. Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up. Frontiers in endocrinology 11:588024(2020). https://doi.org/10.3389/fendo.2020.588024
20. Wilson L, Huang W, Chen L, Ting J, Cao V. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association 27:1043-1052(2017). https://doi.org/10.1089/thy.2016.0572
21. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR American journal of roentgenology 195:281-289(2010). https://doi.org/10.2214/ajr.09.4110
22. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. Journal of Cancer 1:80-92(2010). https://doi.org/10.7150/jca.1.80
23. Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 143:35-42(2008). https://doi.org/10.1016/j.surg.2007.06.011
24. Lee YH, Lee YM, Sung TY, et al. Is Male Gender a Prognostic Factor for Papillary Thyroid Microcarcinoma? Annals of surgical oncology 24:1958-1964(2017). https://doi.org/10.1245/s10434-017-5788-4
25. Lin JD, Hsueh C, Chao TC. Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis. Medicine (Baltimore) 94:e1063(2015). https://doi.org/10.1097/md.0000000000001063
26. Ding J, Wu W, Fang J, Zhao J, Jiang L. Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma. Scientific reports 10:4141(2020). https://doi.org/10.1038/s41598-020-60199-9
27. Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M. Papillary thyroid carcinoma: factors influencing recurrence and survival. Annals of surgical oncology 15:1518-1522(2008). https://doi.org/10.1245/s10434-008-9859-4
28. Grogan RH, Kaplan SP, Cao H, et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 154:1436-1446; discussion 1446-1437(2013). https://doi.org/10.1016/j.surg.2013.07.008
29. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature reviews Cancer 13:184-199(2013). https://doi.org/10.1038/nrc3431
30. Jin Y, Van Nostrand D, Cheng L, Liu M, Chen L. Radioiodine refractory differentiated thyroid cancer. Critical reviews in oncology/hematology 125:111-120(2018). https://doi.org/10.1016/j.critrevonc.2018.03.012
31. Kim H, Park SY, Jung J, et al. Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer. Scientific reports 9:18745(2019). https://doi.org/10.1038/s41598-019-55370-w